<section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><text>

Provided by The Leukemia & Lymphoma Society and Medical Learning Institute, Inc.



LEUKEMIA & LYMPHOMA

<page-header><section-header><text><section-header><section-header><text><list-item><list-item><list-item><list-item><list-item><list-item>





Accreditation, Credit and Support

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and The Leukemia & Lymphoma Society. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Medical Learning Institute, Inc. (MLI) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

	NIA A	0480
" REOL	01	1
	ERED	20

Registered Nursing Credit Designation

Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.0 continuing education contact hour through the California Board of Registered Nursing.

Support Statement

There is no commercial support associated with this CE activity.

Providers

This activity is provided by The Leukemia & Lymphoma Society and Medical Learning Institute, Inc.



4

DISCLOSURE

Disclosure & Conflict of Interest Policy Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.

Planning Committee and Content/Peer Reviewers The planners and content/peer reviewers from Medical Learning Institute, Inc. and The Leukemia & Lymphoma Society do not have any relevant financial relationships to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the accredited CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not mean to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturers product information, and comparison with recommendations of other authorities.

About this Activity

Medical Learning Institute, Inc. and The Leukemia & Lymphoma Society are responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.



6

SPEAKERS


Aref Al-Kali, MD

Professor of Medicine MDS Clinic Director Acute Myeloid Group Chair Section Head **Division of Hematology** Mayo Clinic Rochester, MN

Jennifer Andres, MSN, RN, FNP-C

Outpatient Hematology Nurse Practitioner Mayo Clinic Phoenix, AZ









There are no fees for participating in or receiving credits for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.


Learners must participate in the entire CE activity, complete, and submit the evaluation form to earn credit. Once submitted, the certificate will be generated. If you have questions regarding the receipt of your certificate, please contact ndane@mlieducation.org.














MDS 2022		12
WHO	ICC	
MDS 5q	MDS Del 5q	
MDS SF3B1	MDS SF3B1	
MDS BiTP53	MDS or MDS/AML TP53	
MDS-LB	MDS-NOS (SLD/MLD)	
MDS-h		
MDS IB	MDS-EB	
	MDS/AML	
Arber D et al, Blood 2022, 1200-28. Khoury J et al. Leukemia 2022, 1703-1719	Society	

























ELN	2022		19
F	Risk category†	Genetic abnormality	
F	avorable	 t(8;21)(q22;q22.1)/RUNX1::RUNX1T1†,‡ inv(16)(p13.1q22) or t(16;16)(p13.1;q22)/CBFB::MYH11†,‡ Mutated NPM1†,§ without FLT3-ITD bZIP in-frame mutated CEBPAII 	
l	ntermediate	 Mutated NPM1†,§ with FLT3-ITD Wild-type NPM1 with FLT3-ITD (without adverse-risk genetic lesions) t(9;11)(p21.3;q23.3)/MLLT3::KMT2A†,¶ Cytogenetic and/or molecular abnormalities not classified as favorable or adverse 	
A	Adverse	 t(6;9)(p23.3;q34.1)/DEK::NUP214 t(v;11q23.3)/KMT2A-rearranged# t(9;22)(q34.1;q11.2)/BCR::ABL1 t(8;16)(p11.2;p13.3)/KAT6A::CREBBP inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2)/ GATA2, MECOM(EVI1) t(3q26.2;v)/MECOM(EVI1)-rearranged -5 or del(5q); -7; -17/abn(17p) Complex karyotype,** monosomal karyotype†† Mutated ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2‡‡ Mutated TP53^a 	
	al, Diagnosis and management of AML in adults expert panel on behalf of the ELN, Blood, 2022,		LEUKEMIA & LYMPHOMA SOCIETY*


Favorable	
l N T	 t(8;21)(q22;q22.1)/RUNX1::RUNX1T1†,‡ inv(16)(p13.1q22) or t(16;16)(p13.1;q22)/ CBFB::MYH11†,‡ Mutated NPM1†,§ without FLT3-ITD bZIP in-frame mutated CEBPA
Intermediate N S I V E	 Mutated NPM1†,§ with FLT3-ITD Wild-type NPM1 with FLT3-ITD (without adverse-risk genetic lesions) t(9;11)(p21.3;q23.3)/MLLT3::KMT2A†,¶ Cytogenetic and/or molecular abnormalities not classified as favorable or adverse
Adverse	 t(6;9)(p23.3;q34.1)/DEK::NUP214 t(v;11q23.3)/KMT2A-rearranged# t(9;22)(q34.1;q11.2)/BCR::ABL1 t(8;16)(p11.2;p13.3)/KAT6A::CREBBP inv(3)(q21.3q26.2) or t(3:3)(q21.3;q26.2)/ GATA2, MECOM(EVI1) t(3q26.2;v)/MECOM(EVI1)-rearranged -5 or del(5q); -7; -17/abn(17p) Complex karyotype,** monosomal karyotype†† Mutated ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2‡‡ Mutated TP53^a

Gene	Correlation	Rx	
SF3B1	Ring sideroblast	Luspatercept, imetelstat	
IDH1	Cbc ~	Ivosidenib/Olutasidenib, HMA+VEN	
IDH2	Cbc ~	Enasidenib, HMA+VEN	
FLT3	AML transformation	Gilteritinib	
NPM1	AML-defining	CTX vs HMA+VEN, Menin-i	
RUNX1	AML transformation	HMA+VEN	
DDX41	Germline ?, cbc ~	HMA+VEN, LEN	
STAT3	LGL	ISA	
PIGA1	PNH	Complement inhibitor	
UBA1	VEXAS	HMA,, JAKi	
TP53	T-MN	? PO DAC	






















AZA-001: Phase III Study


Fenaux P, et al. Lancet Oncol. 2009;10:223-32.

	Total ITT (n=358)			BSC only (n=2)	22)		Low-dose cyt	arabine (n=94)	Intensive ch	Intensive chemotherapy (n=42)			
	Azacitidine (n=179)	CCR (n=179)	p value*	Azacitidine (n=117)	BSC (n=105)	p value*	Azacitidine (n=45)	Low-dose cytarabine (n=49)	p value*	Azacitidine (n=17)	Intensive chemotherapy (n=25)	p value*		
Haematological resp	oonse													
Any remission	51 (29%)	21 (12%)	0.0001	32 (27%)	5 (5%)	<0.0001	14 (31%)	6 (12%)	0.042	5 (29%)	10 (40%)	0.53		
Complete remission	30 (17%)	14 (8%)	0.015	14 (12%)	1(1%)	0.0008	11 (24%)	4 (8%)	0.047	5 (29%)	9 (36%)	0.75		
Partial remission	21 (12%)	7 (4%)	0.0094	18 (15%)	4 (4%)	0.0058	3 (7%)	2 (4%)	0.67	0	1(4%)	1.00		
Stable disease	75 (42%)	65 (36%)	0.33	52 (44%)	41 (39%)	0.50	15 (33%)	18 (37%)	0.83	8 (47%)	6 (24%)	0.18		
Haematological imp	rovement†													
Any improvement	87/177 (49%)	51/178(29%)	<0.0001	57/115 (50%)	32/105(31%)	0.0058	24/45 (53%)	12/48 (25%)	0.0061	6/17 (35%)	7/25 (28%)	0.74		
Major erythroid improvement	62/157 (40%)	17/160(11%)	<0.0001	39/100(39%)	8/96 (8%)	<0.0001	19/43 (44%)	4/41 (10%)	0.0005	4/14 (29%)	5/23 (22%)	0.70		
Major platelet improvement	46/141 (33%)	18/129(14%)	0.0003	27/89 (30%)	8/78 (10%)	0.0020	14/37 (38%)	6/31 (19%)	0-12	5/15 (33%)	4/20 (20%)	0.45		
Major neutrophil improvement	25/131 (19%)	20/111 (18%)	0.87	13/85 (15%)	13/66 (20%)	0.52	9/33 (27%)	3/28 (11%)	0-12	3/13 (23%)	4/17 (24%)	1.00		











LEUKEMIA & LYMPHOMA SOCIETY°

Results: Efficacy Response Treated Patients (N=133), n (%) 95% CI Response category Complete response (CR) 29 (22) (15.1,29.8) Median CR duration was 14.0 Partial response (PR) 0 months Marrow CR (mCR) 43 (32.3%) (24.5, 41.0)mCR with hematologic improvement 22 (16.5%) (10.7,24.0) Median duration of best Hematologic improvement (HI) 10 (7.5%) (3.7,13.4) response was 12.7 months HI-erythroid 2 (1.5%) (0.2, 5.3)• 34 (26%) of subjects proceeded **HI-neutrophils** 1 (0.8%) (0.0,4.1) to HCT HI-platelet 7 (5.3%) (2.1, 10.5)Overall response (CR + PR + mCR + HI) 82 (61.7) (52.8,69.9) **Progressive Disease** 6 (4.5%) (1.7, 9.6)No Response 28 (21.1%) (14.5, 29.0) Non-evaluable 17 (12.8%) (7.6, 19.7)




Prolonged Survival in Bi-Allelic TP53-Mutated (TP53mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02)




35

Efficacy and Safety of Lenalidomide in Intermediate-2 or High-Risk Myelodysplastic Syndromes with 5q Deletion: Results of a Phase 2 Study

actor Category	n	No. of CRs	CR, %	P
Cytogenetic				
Isolated del 5q	9	6	67	< .001
Single additional abnormality	11	1	9	
> 1 additional abnormalities	27	0	0	
Bone marrow blasts, %				
< 20%	29	6	21	.16
> 20%	18	1	5	
Baseline platelet count, G/L				
> 100	20	7	35	< .001
< 100	27	0	0	







Summary of AE

Any AEs, n (%)	78 (100)
Neutropenia ^a	65 (83)
Febrile neutropenia	38 (49)
Nausea	43 (55)
Constipation	42 (54)
Diarrhea	38 (49)
Thrombocytopeniab	38 (49)
Vomiting	32 (41)
Leukopenia ^c	30 (38)
Anemiad	23 (29)
Fatigue	20 (26)
Hypokalemia	16 (21)
Grade 3/4 AEs, n (%)	75 (96)
Neutropeniaª	64 (82)
Febrile neutropenia	38 (49)
Thrombocytopenia ^b	33 (42)
Leukopenia	30 (38)
Anemiad	18 (23)

Any SAEs, n (%) 57 Neutropenia ^a 38 Febrile neutropenia 35 Pneumonia 5 Diverticulitis 4 • Overall, 74 patients (95%) required median time to delay 15.0 days (rar • 43 patients (55%) had ≥2 Ven dose • AEs 59 (80%); hematologic toxi logistics/scheduling 19 (26%).	49) 45)
Neutropenia ^a 38 Febrile neutropenia 35 Pneumonia 5 Diverticulitis 4 • Overall, 74 patients (95%) required median time to delay 15.0 days (rar • 43 patients (55%) had ≥2 Ven dose • AEs 59 (80%); hematologic toxi	49) 45)
Neutropenia ^a 38 Febrile neutropenia 35 Pneumonia 5 Diverticulitis 4 • Overall, 74 patients (95%) required median time to delay 15.0 days (rar • 43 patients (55%) had ≥2 Ven dose • AEs 59 (80%); hematologic toxi	49) 45)
Neutropenia ^a 38 Febrile neutropenia 35 Pneumonia 5 Diverticulitis 4 • Overall, 74 patients (95%) required median time to delay 15.0 days (rar • 43 patients (55%) had ≥2 Ven dose • AEs 59 (80%); hematologic toxi	49) 45)
Pneumonia 5 Diverticulitis 4 • Overall, 74 patients (95%) required median time to delay 15.0 days (rar • 43 patients (55%) had ≥2 Ven dose • AEs 59 (80%); hematologic toxi	,
Diverticulitis 4 • Overall, 74 patients (95%) required median time to delay 15.0 days (rar • 43 patients (55%) had ≥2 Ven dose • AEs 59 (80%); hematologic toxi	6)
 Overall, 74 patients (95%) required median time to delay 15.0 days (rar 43 patients (55%) had ≥2 Ven dose AEs 59 (80%); hematologic toxi 	
median time to delay 15.0 days (rar • 43 patients (55%) had ≥2 Ven dose • AEs 59 (80%); hematologic toxi	5)
 A total of 35% of patients required reduction^e AEs 6 (21%); starting CYP3A ir (71%); other 7 (25%) A total of 33% of patients required reduction^e 30-day mortality after first dose wa	ge 3–99) nterruptions sity 27 (37%); ther 41 (55%) 11 Ven dose hibitor 20


Garcia J et al, ASH 2020








41


Prior Hypomethylating Agent use Lacks Impact on Clinical Outcome in Patients with Secondary Acute Myeloid Leukemia Arising from Myelodysplastic Syndromes Treated with Standard Induction Chemotherapy













Final Phase 1 Results of Ivosidenib for Patients with Mutant IDH1 Relapsed/Refractory Myelodysplastic Syndrome


		26% N	/[DS-I	EE					
	Efficacy outcomes	MDS substudy efficacy analysis set (N = 18)		HM/ IC						
	CR + PR	7 (38.9%)		- HMJ - HMA, I - HMJ	NV			• •		
	Time to CR + PR, median mo (min, max)	1.87 (1.0, 5.6)	Proven	HM/ HM/ HM/ HM/ HM/ HM/	*	•	•	•	Best respon	ese 📕 CR 🝵 mCR 📑 SD 📕 PDis
	mCR	8 (44.4%)		- HMA, C - HM/ - HM/	ther ther	-				Hill for non-CR/PR subjects CR+PR response Disease progression/relapse
	ORR	15 (83.3%)		- IC - HM/ - HM/	*	•		•		Death Progression to AML
	Any HI lineage (CR/PR-)	4 (36.4%)		- HMA, I		3 6 9	12 15	18 21 24 27 30 33 36 39 42 Treatment duration (ment)	45 48 51 54 57 60 16)	♦ HSCT
	7-y OS	46.3 %								
relapsed/r	CD. Final phase 1 substudy results or efractory myelodysplastic syndrome © 2024 American Society of Hemat	e, Blood Adv, 2024,	t ID	H1		(erican Society of Hem g hematologists conquer blood diseases		LEUKEMIA & LYMPHOMA SOCIETY*

































VEN VS AZA PBC	O (VIALE-A	v)	
	Aza Ven	Aza PBO	P value
cCR	66.4%	28.3%	<.001
cCR- end of C1	43.4%	7.6%	<.001
CR	36.7%	17.9%	<.001
Median time to response	1.3 m (0.6-9.9)	2.8 (0.8-13.2)	
Median response duration	17.5 m	13.4 m	
mOS	14.7 m	9.6 m	< .001
mEFS	9.8 m	7 m	<.001
9 et al. N Engl J Med 2020;383:617-629		S The	NEW ENGLAND URNAL of MEDIC

	Aza Ven	Aza PBO	P value
DH cCR	75.4%	10.7%	<.001
FLT3 cCR	72.4%	36.4%	.02
NPM1 cCR	66.7%	23.5%	.01
P53 cCR	55.3%	0	<.001
MRD-	23.4%	7.6%	
et al. N Engl J Med 2020;383:617-629		(\mathfrak{S})	The NEW ENGLAND JOURNAL of MEDICINI


AZA V	EN vs AZA PBO (VIALE-A)		59
		Aza Ven	Aza PBO	
	dn-AML OS	14.1 m	9.6 m	
	s-AML OS	16.4 m	10.6 m	
	Int-risk AML OS	20.8 m	12.4 m	
	Poor risk AML OS	7.6 m	6 m	
	30-D mortality	7%	6%	
DiNardo CD (et al. N Engl J Med 2020;383:617-629		The NEW ENGLAN JOURNAL of MED	ID LEUKEMIA & LYMPHOMA SOCIETY
Э				






























Instructions For Credit

Participants must complete the evaluation to receive credit. After completing this process, your certificate will automatically generate.

Link to complete evaluation: <u>https://lls.link/MDS</u>

OR scan the QR code:



For questions or concerns, please contact Profeducation@lls.org

